Business Trip

In this 3-part series on microdosing, we explore the science, history, and its clinical potential. 

The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a placebo effect?

In part 1, we chat with James Fadiman, Ph.D who has been researching psychedelics since the 1960’s. He's the author of several books, including the Psychedelic Explorer's Guide. He has collected thousands of microdosing reports and even has his own microdosing protocol - called the Fadiman protocol. When we talk about standing on the shoulders of giants, James Fadiman is one of them.

Credits: 

Created by Greg Kubin and Matias Serebrinsky
Host:  Greg Kubin
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Links to topics discussed in this episode:

Jim's microdosing website
Sofia University
The Psychedelic Explorer's Guide
Psychedelics Promote Structural and Functional Neural Plasticity (Ly et al, 2018)

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.

Credits: 

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center.  She is the Director at the Mental Health Patient Care Center at the James J. Peters VA Medical Center, Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai Hospital, as well as Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.

Credits: 

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources.

In this episode, we discuss:

• The journey from idea to 100+ therapist members
• How ketamine-assisted therapy works and the Journey Clinical's vision for the future
• Balancing growth with protecting the relationship between patient and therapist

Credits: 

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. 

In this episode, we discuss:

• How Osmind makes data-driven decisions 
• Osmind’s quick growth in only 2 years
• What it will take for insurance to cover ketamine therapy, as well as other psychedelic therapies

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.

In this episode, we discuss:

• Tim’s background in healthcare finance
• Investing in classic psychedelic compounds vs. 2nd generation compounds
• Hallmarks of a good first meeting with a prospective investment

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round.

In this episode, we discuss:

• Tom and Dillan’s experience in YCombinator and raising an $11.5M seed round
• Tom’s friendship with the late psychedelic chemist Alexander Shulgin
• Mindstate’s lead programs
• The role of mystical states in the healing process

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love

Today’s episode announces the launch of PsyMed Ventures, a $25M fund we started with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies. PsyMed Ventures is a community-focused fund and syndicate providing capital and support to companies revolutionizing how mental health is treated.

In this episode, we discuss:

• $25M fund to invest in psychedelic medicine companies and mental health tech
• How we evaluate new companies
• Exciting trends in mental health research
• Our story from starting Business Trip to launching an investment syndicate and fund

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love

Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy.

In this episode, we discuss:

• MAPS’ protocol and strategy behind FDA clinical trial for PTSD
• Amy’s views on the state of the industry, patents, and how to prioritize accessibility
• The unique business model between MAPS and MAPS PBC
• Psychedelics for kids

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin and Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: Focus Does the Girl by Muted Circus

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable.

In this episode, we discuss:

• Ketamine-assisted psychotherapy and the difference between high and low dose ketamine treatments
• What it takes to get a for-profit clinic off the ground while running a non-profit organization
• Sage Institute’s mission to make ketamine-assisted psychotherapy affordable for everyone
• Genesee’s long term goals for the future of psychedelic medicine

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Read the transcript here.

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: Flocean by Zack Frank